| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 22 | 2017 | 1426 | 2.420 |
Why?
|
| Exosomes | 7 | 2018 | 97 | 2.330 |
Why?
|
| Cell Adhesion | 20 | 2020 | 209 | 2.220 |
Why?
|
| alpha-Fetoproteins | 7 | 2022 | 29 | 1.680 |
Why?
|
| Blood Proteins | 6 | 2010 | 65 | 1.460 |
Why?
|
| Antigens, Differentiation | 9 | 2001 | 24 | 1.390 |
Why?
|
| Galectin 3 | 13 | 2006 | 26 | 1.190 |
Why?
|
| Cell Line, Tumor | 19 | 2022 | 2128 | 1.080 |
Why?
|
| Histones | 2 | 2018 | 177 | 1.070 |
Why?
|
| Annexin A6 | 5 | 2020 | 14 | 1.060 |
Why?
|
| Focal Adhesions | 3 | 2014 | 15 | 0.980 |
Why?
|
| Neoplasm Invasiveness | 6 | 2018 | 247 | 0.970 |
Why?
|
| Cell Membrane | 7 | 2018 | 360 | 0.850 |
Why?
|
| Breast | 5 | 2013 | 134 | 0.810 |
Why?
|
| Carcinoma | 3 | 2010 | 94 | 0.780 |
Why?
|
| Laminin | 8 | 2014 | 59 | 0.760 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 58 | 0.750 |
Why?
|
| Neoplasms | 4 | 2018 | 1033 | 0.700 |
Why?
|
| Syndecan-4 | 1 | 2018 | 4 | 0.680 |
Why?
|
| Durapatite | 1 | 2018 | 16 | 0.670 |
Why?
|
| Carcinogens, Environmental | 2 | 2015 | 34 | 0.660 |
Why?
|
| Cell Proliferation | 12 | 2021 | 1149 | 0.650 |
Why?
|
| Humans | 50 | 2022 | 34853 | 0.640 |
Why?
|
| Signal Transduction | 6 | 2022 | 1802 | 0.600 |
Why?
|
| Astrocytoma | 1 | 2016 | 13 | 0.600 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 794 | 0.580 |
Why?
|
| Metalloendopeptidases | 4 | 1998 | 15 | 0.580 |
Why?
|
| Chemotaxis | 2 | 2013 | 57 | 0.560 |
Why?
|
| Cell Movement | 9 | 2020 | 545 | 0.550 |
Why?
|
| Calcium | 8 | 2022 | 445 | 0.550 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 105 | 0.540 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 211 | 0.530 |
Why?
|
| Nanoparticles | 1 | 2018 | 294 | 0.490 |
Why?
|
| Animals | 25 | 2021 | 14307 | 0.480 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 28 | 0.470 |
Why?
|
| Extracellular Space | 2 | 2018 | 33 | 0.460 |
Why?
|
| Chalcone | 1 | 2013 | 5 | 0.460 |
Why?
|
| Cystatins | 2 | 2010 | 17 | 0.430 |
Why?
|
| Mice | 14 | 2021 | 5668 | 0.430 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 781 | 0.410 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 107 | 0.410 |
Why?
|
| Matrix Metalloproteinase 9 | 6 | 2013 | 88 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 592 | 0.400 |
Why?
|
| Endocytosis | 3 | 2020 | 104 | 0.390 |
Why?
|
| Neoplastic Processes | 1 | 2010 | 2 | 0.380 |
Why?
|
| Disease Progression | 4 | 2021 | 580 | 0.380 |
Why?
|
| Tumor Cells, Cultured | 12 | 2002 | 480 | 0.370 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2010 | 70 | 0.370 |
Why?
|
| Gelatinases | 4 | 1998 | 8 | 0.350 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 183 | 0.340 |
Why?
|
| Collagenases | 4 | 1998 | 27 | 0.340 |
Why?
|
| Female | 21 | 2020 | 19873 | 0.340 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2004 | 166 | 0.330 |
Why?
|
| Fibronectins | 3 | 2014 | 65 | 0.310 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2013 | 176 | 0.300 |
Why?
|
| Collagen | 4 | 2013 | 162 | 0.300 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2006 | 45 | 0.280 |
Why?
|
| Neoplasm Proteins | 3 | 2022 | 203 | 0.270 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2005 | 6 | 0.260 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2004 | 39 | 0.260 |
Why?
|
| Cell Line | 7 | 2014 | 1289 | 0.260 |
Why?
|
| Liposomes | 1 | 2005 | 107 | 0.260 |
Why?
|
| Annexin A4 | 1 | 2004 | 1 | 0.260 |
Why?
|
| Annexin A2 | 1 | 2004 | 6 | 0.260 |
Why?
|
| Lipid Bilayers | 1 | 2005 | 66 | 0.260 |
Why?
|
| RNA Interference | 2 | 2018 | 225 | 0.250 |
Why?
|
| Extracellular Matrix | 2 | 2002 | 111 | 0.240 |
Why?
|
| Proteoglycans | 2 | 2014 | 46 | 0.240 |
Why?
|
| Elastin | 2 | 2001 | 37 | 0.230 |
Why?
|
| Plasminogen | 2 | 2013 | 10 | 0.230 |
Why?
|
| Environmental Exposure | 2 | 2015 | 207 | 0.230 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 859 | 0.230 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2002 | 14 | 0.230 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 151 | 0.220 |
Why?
|
| Hypercalcemia | 1 | 2022 | 12 | 0.220 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2021 | 9 | 0.210 |
Why?
|
| Protein Binding | 6 | 2005 | 913 | 0.210 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2021 | 18 | 0.210 |
Why?
|
| Matrix Metalloproteinase 2 | 5 | 2003 | 47 | 0.200 |
Why?
|
| Ligands | 2 | 2018 | 317 | 0.190 |
Why?
|
| Cattle | 3 | 2013 | 472 | 0.190 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 2020 | 2 | 0.190 |
Why?
|
| Calcium Channels | 1 | 2020 | 72 | 0.180 |
Why?
|
| beta-Cyclodextrins | 2 | 2011 | 22 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 184 | 0.170 |
Why?
|
| Pancreas | 1 | 2018 | 32 | 0.170 |
Why?
|
| Receptor, Insulin | 1 | 2018 | 22 | 0.170 |
Why?
|
| MAP Kinase Signaling System | 2 | 2010 | 162 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 3 | 2010 | 1530 | 0.160 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 210 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1998 | 68 | 0.160 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2017 | 14 | 0.160 |
Why?
|
| Gene Expression | 4 | 2016 | 639 | 0.150 |
Why?
|
| Cell Culture Techniques | 1 | 1997 | 136 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2021 | 386 | 0.140 |
Why?
|
| Hemagglutinins | 2 | 1993 | 8 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 161 | 0.140 |
Why?
|
| Flow Cytometry | 2 | 2011 | 392 | 0.140 |
Why?
|
| Asialoglycoproteins | 1 | 1995 | 3 | 0.140 |
Why?
|
| Mice, Nude | 1 | 2016 | 323 | 0.140 |
Why?
|
| Hazardous Substances | 1 | 2015 | 18 | 0.130 |
Why?
|
| Protein Transport | 2 | 2006 | 286 | 0.130 |
Why?
|
| Cells, Cultured | 6 | 2006 | 1442 | 0.130 |
Why?
|
| Polysaccharide-Lyases | 1 | 2014 | 10 | 0.130 |
Why?
|
| Heparin | 1 | 2014 | 34 | 0.130 |
Why?
|
| Heparitin Sulfate | 1 | 2014 | 23 | 0.130 |
Why?
|
| Mice, Knockout | 2 | 2010 | 897 | 0.130 |
Why?
|
| Male | 5 | 2022 | 18870 | 0.120 |
Why?
|
| Cytoplasm | 1 | 2014 | 135 | 0.120 |
Why?
|
| Cell Division | 5 | 2004 | 296 | 0.120 |
Why?
|
| Models, Biological | 2 | 2012 | 642 | 0.120 |
Why?
|
| Quinazolines | 1 | 2013 | 31 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2013 | 89 | 0.120 |
Why?
|
| Cell Nucleus | 2 | 2014 | 351 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 73 | 0.110 |
Why?
|
| Biocompatible Materials | 1 | 2013 | 75 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2013 | 79 | 0.110 |
Why?
|
| Mice, SCID | 1 | 2013 | 143 | 0.110 |
Why?
|
| Colon | 1 | 2013 | 98 | 0.110 |
Why?
|
| Epithelium | 4 | 1997 | 74 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 209 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 242 | 0.110 |
Why?
|
| Annexins | 1 | 2011 | 7 | 0.100 |
Why?
|
| Fluorescence Recovery After Photobleaching | 1 | 2011 | 7 | 0.100 |
Why?
|
| Receptors, Cell Surface | 2 | 2004 | 135 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1300 | 0.100 |
Why?
|
| Blotting, Western | 3 | 2011 | 834 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 181 | 0.100 |
Why?
|
| Biological Transport | 1 | 2011 | 175 | 0.100 |
Why?
|
| Genes, ras | 1 | 1991 | 22 | 0.100 |
Why?
|
| Trypanosoma cruzi | 2 | 2004 | 144 | 0.100 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2010 | 13 | 0.100 |
Why?
|
| Glycerol | 1 | 2010 | 29 | 0.100 |
Why?
|
| Ions | 1 | 2010 | 61 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2010 | 13 | 0.090 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 200 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 44 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 137 | 0.090 |
Why?
|
| Binding Sites | 3 | 1998 | 597 | 0.090 |
Why?
|
| Microtubules | 1 | 1990 | 113 | 0.090 |
Why?
|
| Carbohydrate Metabolism | 2 | 2002 | 20 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 143 | 0.080 |
Why?
|
| Structure-Activity Relationship | 1 | 2010 | 376 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 1991 | 239 | 0.080 |
Why?
|
| Neurodegenerative Diseases | 1 | 2010 | 119 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 608 | 0.080 |
Why?
|
| Hypoxanthines | 1 | 1987 | 3 | 0.080 |
Why?
|
| Phorbol Esters | 1 | 1987 | 8 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 391 | 0.080 |
Why?
|
| Cricetinae | 3 | 2002 | 217 | 0.080 |
Why?
|
| Prognosis | 2 | 2020 | 707 | 0.080 |
Why?
|
| Integrins | 2 | 1998 | 49 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 173 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 1999 | 485 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 413 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2010 | 486 | 0.070 |
Why?
|
| Proteomics | 1 | 2009 | 302 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 756 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 117 | 0.070 |
Why?
|
| Transfection | 3 | 2004 | 496 | 0.070 |
Why?
|
| Membrane Fluidity | 1 | 2005 | 11 | 0.070 |
Why?
|
| Epithelial Cells | 3 | 1997 | 366 | 0.070 |
Why?
|
| Cell Membrane Permeability | 1 | 2005 | 49 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 1998 | 984 | 0.070 |
Why?
|
| Immunoblotting | 2 | 1998 | 170 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 41 | 0.070 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2005 | 21 | 0.060 |
Why?
|
| Binding, Competitive | 2 | 2013 | 103 | 0.060 |
Why?
|
| Morpholines | 1 | 2005 | 65 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 1998 | 298 | 0.060 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2004 | 28 | 0.060 |
Why?
|
| Chromones | 1 | 2005 | 51 | 0.060 |
Why?
|
| Collagen Type IV | 1 | 2004 | 48 | 0.060 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2004 | 50 | 0.060 |
Why?
|
| Kininogens | 1 | 2003 | 4 | 0.060 |
Why?
|
| Antibodies | 1 | 2004 | 135 | 0.060 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 100 | 0.060 |
Why?
|
| Calcium Signaling | 1 | 2005 | 95 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2004 | 93 | 0.060 |
Why?
|
| Cystatin C | 1 | 2003 | 21 | 0.060 |
Why?
|
| Magnesium | 1 | 2004 | 95 | 0.060 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2003 | 21 | 0.060 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2004 | 84 | 0.060 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2004 | 127 | 0.060 |
Why?
|
| Multigene Family | 1 | 2003 | 105 | 0.060 |
Why?
|
| Skin | 1 | 2004 | 173 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 229 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 245 | 0.060 |
Why?
|
| CHO Cells | 1 | 2002 | 107 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 1995 | 1124 | 0.050 |
Why?
|
| Receptors, Galanin | 1 | 2002 | 1 | 0.050 |
Why?
|
| Caveolae | 1 | 2001 | 8 | 0.050 |
Why?
|
| Organogenesis | 1 | 2002 | 16 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2001 | 35 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 1490 | 0.050 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2021 | 8 | 0.050 |
Why?
|
| Cell Size | 1 | 2001 | 42 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 56 | 0.050 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 40 | 0.050 |
Why?
|
| Variant Surface Glycoproteins, Trypanosoma | 1 | 2000 | 8 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 32 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2020 | 87 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 56 | 0.050 |
Why?
|
| Molecular Weight | 2 | 2000 | 161 | 0.050 |
Why?
|
| Mutation | 1 | 2004 | 1023 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 164 | 0.040 |
Why?
|
| RNA, Transfer | 2 | 1989 | 26 | 0.040 |
Why?
|
| Integrin alpha1beta1 | 1 | 1998 | 2 | 0.040 |
Why?
|
| Hemagglutination | 1 | 1998 | 3 | 0.040 |
Why?
|
| Receptors, Estrogen | 2 | 1996 | 145 | 0.040 |
Why?
|
| Lectins | 1 | 1998 | 20 | 0.040 |
Why?
|
| Dimerization | 1 | 1998 | 102 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1998 | 195 | 0.040 |
Why?
|
| Africa | 1 | 1997 | 62 | 0.040 |
Why?
|
| Age of Onset | 1 | 2017 | 98 | 0.040 |
Why?
|
| Integrin alpha6beta1 | 1 | 1997 | 2 | 0.040 |
Why?
|
| Milk, Human | 1 | 1997 | 29 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2017 | 155 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 102 | 0.040 |
Why?
|
| Apoptosis | 1 | 2004 | 1317 | 0.040 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 1996 | 5 | 0.040 |
Why?
|
| Enzyme Precursors | 1 | 1996 | 10 | 0.040 |
Why?
|
| Biopsy | 1 | 1997 | 151 | 0.040 |
Why?
|
| Phenotype | 2 | 1991 | 650 | 0.040 |
Why?
|
| Phenylacetates | 1 | 1996 | 2 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1996 | 18 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2019 | 878 | 0.040 |
Why?
|
| Cell Survival | 1 | 2019 | 818 | 0.040 |
Why?
|
| Amino Sugars | 1 | 1995 | 2 | 0.040 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 1995 | 3 | 0.040 |
Why?
|
| Galactosides | 2 | 1993 | 11 | 0.040 |
Why?
|
| Galectins | 2 | 1993 | 27 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1993 | 185 | 0.030 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 1995 | 8 | 0.030 |
Why?
|
| Polysaccharides | 1 | 1995 | 55 | 0.030 |
Why?
|
| Solubility | 1 | 1995 | 115 | 0.030 |
Why?
|
| Dopamine Agonists | 1 | 1995 | 29 | 0.030 |
Why?
|
| Species Specificity | 1 | 1995 | 233 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 1994 | 5 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 641 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1994 | 86 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 1995 | 423 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 1994 | 186 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1056 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 81 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 114 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 107 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 638 | 0.030 |
Why?
|
| Lysosomes | 1 | 2013 | 80 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 91 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 133 | 0.030 |
Why?
|
| Cytosol | 1 | 1992 | 85 | 0.030 |
Why?
|
| Proteins | 1 | 1994 | 352 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 1993 | 562 | 0.030 |
Why?
|
| Inositol Phosphates | 1 | 1991 | 7 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2017 | 1961 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 1991 | 87 | 0.030 |
Why?
|
| Monocytes | 1 | 1993 | 258 | 0.030 |
Why?
|
| Kinetics | 1 | 1992 | 650 | 0.020 |
Why?
|
| Calcimycin | 1 | 1990 | 11 | 0.020 |
Why?
|
| Bucladesine | 1 | 1990 | 7 | 0.020 |
Why?
|
| Colchicine | 1 | 1990 | 15 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1991 | 196 | 0.020 |
Why?
|
| Tubulin | 1 | 1990 | 80 | 0.020 |
Why?
|
| Guanine | 1 | 1989 | 45 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1990 | 125 | 0.020 |
Why?
|
| Hypoxanthine | 1 | 1987 | 2 | 0.020 |
Why?
|
| Methylcholanthrene | 1 | 1987 | 4 | 0.020 |
Why?
|
| Nucleotides | 1 | 1987 | 33 | 0.020 |
Why?
|
| Tamoxifen | 2 | 1996 | 61 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2004 | 126 | 0.020 |
Why?
|
| Estradiol | 2 | 1996 | 244 | 0.020 |
Why?
|
| Rats | 1 | 1991 | 3261 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 9642 | 0.010 |
Why?
|
| Adult | 1 | 1997 | 11034 | 0.010 |
Why?
|
| Lactose | 1 | 2000 | 13 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2000 | 51 | 0.010 |
Why?
|
| Mucins | 1 | 2000 | 33 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2000 | 83 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2000 | 282 | 0.010 |
Why?
|
| Prolactin | 1 | 1995 | 59 | 0.010 |
Why?
|
| Haloperidol | 1 | 1995 | 27 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1993 | 12 | 0.010 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1993 | 18 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1993 | 139 | 0.010 |
Why?
|
| Tretinoin | 1 | 1993 | 50 | 0.010 |
Why?
|
| Actins | 1 | 1993 | 142 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1993 | 550 | 0.010 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1989 | 26 | 0.010 |
Why?
|
| Cricetulus | 1 | 1989 | 74 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1993 | 1152 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 1989 | 140 | 0.010 |
Why?
|
| Pregnancy | 1 | 1989 | 1503 | 0.000 |
Why?
|